Early response to Tezepelumab in type-2 severe asthma patients non-responders to other biological treatments: a real-life study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Early response to Tezepelumab in type-2 severe asthma patients non-responders to other biological treatments: a real-life study

Published:2024-05-09 Issue: Volume: Page:1-4
ISSN:0277-0903
Container-title:Journal of Asthma
language:en
Short-container-title:Journal of Asthma

Author:

Jiménez-Gómez Miguel¹^ORCID,Díaz-Campos Rocío Magdalena¹²,Gimeno-Díaz-De-Atauri Álvaro²³,Fernández-Rodríguez Consuelo²⁴,Fernández-Crespo Jesús²⁴,García-Moguel Ismael²⁴

Affiliation:

1. Department of Pulmonology, Hospital Universitario 12 de Octubre, Madrid, Spain

2. Hospital Universitario 12 de Octubre (imas12), Madrid, Spain

3. Department of Paediatric Pulmonology, Hospital Universitario 12 de Octubre, Madrid, Spain

4. Department of Allergy, Hospital Universitario 12 de Octubre, Madrid, Spain

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/02770903.2024.2349605

Reference12 articles.

1. 2023 GINA Report Global Strategy for Asthma Management and Prevention (GINA 2023). Available at https://ginasthma.org/gina-reports/.

2. Multiple Targets, Multiple Pathways, Multiple Strategies in the Treatment of Asthma

3. Biologic Therapies for Severe Asthma

4. Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma

5. Efficacy of Tezepelumab in Severe, Uncontrolled Asthma: Pooled Analysis of the PATHWAY and NAVIGATOR Clinical Trials

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP